AzTrials
AzTrials

Parkinson DiseasePhase 2NCT04691661

Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease

A Phase 2 study testing Radotinib HCl 50 mg in people with Parkinson Disease, run by Il-Yang Pharm. Co., Ltd. at 7 sites in France.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This is a safety, tolerability, pharmacokinetic and efficacy study in subjects with Parkinson's disease Read more about this study

Who is it for?
Ages 40 to 80 years
Conditions the study is for
Parkinson Disease
What is being tested?
Radotinib HCl 50 mg
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
43 participants
Where
7 sitesFrance
Study dates
9 Sep 2021to 30 Apr 2027
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male and Female from 40 to 80 years old;
  • Diagnosed with "Clinically Probable Parkinson's Disease" according to the MDS clinical diagnostic criteria, with documented onset of symptoms per treating physician's records within three years of the screening visit;
  • Positive DAT-scan (e.g. a striatal dopamine transporter deficit on dopamine transporter imaging by DaT-SPECT, characterized by crescent-shaped areas of asymmetrical aspect, or of symmetrical aspect but of uneven intensity, between the right and the left brain hemisphere) confirmed by local reading;
  • Hoehn \& Yahr stage ≤ 2.5;
  • Without previous symptomatic treatment for PD disease and with current clinical state not requiring started dopaminergic therapy within 6 months from Baseline;
  • Absence of a parkinsonian syndrome and other neurovascular comorbidities, confirmed by MRI
Show all 12Show fewer
  • Female subjects must be not of childbearing potential, e.g., documented evidence that they are surgically sterile (e.g., hysterectomy, partial hysterectomy, bilateral oophorectomy, bilateral tubal ligation), or postmenopausal (at least 12 months since last menses) or using highly effective method of birth control defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly, such as combined hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intra uterine devices (IUDs), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, condom, until at least one month after the last drug intake associated to a negative pregnancy test at screening;
  • Covered by Health Insurance System;
  • Able to understand and to sign the informed consent prior to screening;
  • Blood Pressure (BP) and Heart Rate (HR) considered NCS by Investigator;
  • Electrocardiogram (ECG) recording on a 12-lead ECG considered NCS by Investigator;
  • Laboratory parameters within the normal range of the laboratory. Individual values out of the normal range can be accepted if judged clinically non relevant by the Investigator.

Who cannot join

  • Atypical Parkinsonism or drug-induced Parkinsonism;
  • Current, or within 60 days of screening, use of any prescription, investigational, or over the counter medication for the symptomatic treatment of PD or to slow the progression of PD.
  • Prior use of dopaminergic therapy (e.g., levodopa, dopamine agonist, amantadine, rasagiline) for 30 or more days any time in the past;
  • Cognitive impairment (MMSE ≤ 24);
  • Active psychiatric disorder (mood disorders, hallucinations or delirium with strong functional impact and not controlled by medication or which happened during the last 3 months before inclusion);
  • Severe or uncontrolled chronic disease;
Show all 36Show fewer
  • Significant medical history of congenital or acquired bleeding disorders;
  • Treatment by Deep Brain Stimulation or continuous infusion of apomorphin/dopa gel;
  • Any below impaired cardiac function:
  • LVEF <45% or < lower bound of normal limit of study site (whichever higher), confirmed by echocardiogram (if the subject has already carried out this examination during the last month before inclusion, he/she will be exempted from retaking this examination, but he/she will have to present the echocardiogram as well as the cardiologist's report. If not, this exam should be performed during the screening period)
  • Subjects who cannot have QT intervals measured according to ECG
  • Complete left bundle branch block
  • Subjects with cardiac pacemakers
  • Subjects with congenital long QT syndrome or the family history of known long QT syndrome
  • History of, or presence of symptomatic ventricular or atrial tachyarrhythmias
  • Clinically significant resting bradycardia (< 50 bpm).
  • Mean QTcF >450msec following three consecutive ECG tests at baseline: Screening test will be performed again for QTcF after the adjustment of electrolyte if QTcF >450msec and the electrolyte is not within the normal range
  • Medical history of clinically confirmed myocardial infarction
  • Medical history of unstable angina (within last 12 months)
  • Other clinically significant cardiac disease (e.g. congestive heart failure, or uncontrolled hypertension)
  • Participation in other investigational drug trials within 30 days prior to Screening;
  • Any concomitant medication or medication excluded that could put subject at risk, or interfere with study evaluations;
  • Subjects currently receiving treatment with a strong CYP3A4 inhibitors (e.g. erythromycin, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, mibefradil) or strong CYP3A4 inducers (e.g. dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbitol, St. John's Wort) or therapeutic Cumarin derivatives (e.g. warfarin, acenocoumarol, phenprocoumon) and that can neither stop the administration of these drugs before the start of the IP administration nor switch to other drugs
  • Subjects who are currently receiving treatment with a medication that has the potential to extend QT intervals and can neither stop the administration of the drugs before the start of the IP administration nor switch to other drugs (list of medications that have the potential to prolong QT interval is provided in the Appendix II) If subjects need to start such drug treatments during the study, this will be discussed with the sponsor, IL-YANG PHARM. Co., Ltd.
  • Subjects who are currently receiving treatment with P-gp inducers (e.g. (Ritonavir, Saquinavir, Nelfinavir, Indinavir, Amprenavir, Tipranavir…), Apalutamide, Estrone, Estriol, Trazodone, Vincristine, Tamoxifen, Doxorubicin, Carbamazepine, Oxcarbazepine, Fosphenytoin, Lorlatinib, Phenobarbital, Phenytoin, Propofol, beclomethasone, Dexamethasone, Prednisone, Hydrocortisone, Diclofenac, Rifampicin, Reserpine, Nifedipine, Digoxine, Amiodarone, Spironolactone, Levothyroxine, Tacrolimus, Sirolimus, St. John's Wort (herbal ingredient)) and that can neither stop the administration of these drugs before the start of the IP administration nor switch to other drugs;
  • Gastrointestinal disorder or gastrointestinal disease that may result in a significant change in the absorption of the investigational product;
  • Medical history of acute or chronic pancreatitis within the past one year;
  • Acute or chronic liver, pancreas, or severe kidney disease that are not associated with the disease;
  • Subjects known seropositive to human immunodeficiency virus (HIV), current acute or chronic hepatitis B (hepatitis B surface-antigen positive), hepatitis C, or cirrhosis. Inactive hepatitis B surface antigen (HBsAg) carriers, treated and stable hepatitis B (HBV DNA < 500 IU/mL or site specific local lab normal range lower limit assessed by investigator), and cured hepatitis C subjects can be enrolled;
  • Men subjects who are unwilling to use and appropriate method of contraception during the study;
  • Subjects who have hypersensitivity to active ingredient or any of the excipients of this investigational product;
  • Any medical condition that might interfere with the protocol except those defined in Section 5.3 of the study protocol;
  • Subject unable to attend scheduled visits or to comply to the protocol;
  • Subject under legal guardianship or judicial protection;
  • Subject in the exclusion period of another protocol;
  • No possibility of contact in case of emergency.

Trial locations and contacts

7 sites in 1 country.

7 sites in 1 country

France7 sites

  • CHRU de Lille - Hôpital Roger Salengro

    Lille

  • CHU Limoges

    Limoges

  • CHU de Lyon HCL

    Lyon

  • Hôpital Nantes-Hotel Dieu

    Nantes

  • Hôpital Pitié-Salpêtrière

    Paris

  • Chu La Miletrie

    Poitiers

  • CHU de Rouen

    Rouen

Other trials in France

About this study

Official title: A Randomized Double-blind Placebo-controlled Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Radotinib in Parkinson's Disease

This is a safety, tolerability, pharmacokinetic and efficacy study in subjects with Parkinson's disease

Read the detailed description

This study is will be conducting to determine if Radotinib is safe and can be tolerated by patients with Parkinson's disease (PD) and to learn if Radotinib can be potential therapeutic agents for the treatment of PD.

Radotinib has been approved by Ministry of Food \& Drug Safety of Korea to treat Chronic Myeloid Leukemia (CML) but it has not been approved for PD.

In nonclinical efficacy study, therapeutic effect of Radotinib HCl, c-Abl inhibitor, which exhibits improved pharmacokinetic properties and BBB penetration compared to nilotinib and other c-Abl inhibitors, was tested in a preclinical α-synuclein preformed fibrils (PFF) model of sporadic PD. As a result, the treatment of Radotinib HCl protects the α-synuclein PFFs-induced neuronal toxicity, reduces the PFFs-induced LB/LN-like pathology, and inhibits the PFFs-induced c-Abl activation in neurons. In vivo studies demonstrate that administration of Radotinib HCl prevents dopamine neuron loss and behavioral deficits following α-synuclein PFFs-induced toxicity. Taken together, these findings indicate that Radotinib HCl has beneficial neuroprotective effects in PD and provides strong evidence that selective and brain permeable c-Abl inhibitors can be potential therapeutic agents for the treatment of PD.

These data are very compelling to evaluate the effects of Radotinib in a phase II, randomized, double-blind, placebo-controlled trial in patients with PD.

Being tested
Radotinib HCl 50 mg, Placebo
Medical subject headings
Parkinson Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Radotinib HCl 50 mgDrug

    Also called Radotinib, IY5511

    Enrolled subject will continue to administer Radotinib 50mg/day, 100mg/day, 150mg/day, 200mg/day, depending on the dose level once daily for 6 months.

  • PlaceboDrug

    Placebo

Study groups in NCT04691661
Study groupRoleWhat they receive
Placebo: Dose escalationPlacebo comparatorForty (40) subject will be recruited and randomized into 4 dosing groups. In each dosing group, ten (10) will be randomized and 8 of 10 will receive the active product (Radotinib) and 2 subjects will receive the matching placebo orally once daily for 6 months at each escalating dose level.
Receives: Drug: Placebo
Radotinib HCl: Dose escalationExperimentalForty (40) subject will be recruited and randomized into 4 dosing groups. In each dosing group, ten (10) will be randomized and 8 of 10 will receive the active product (Radotinib) and 2 subjects will receive the matching placebo orally once daily for 6 months at each escalating dose level. The inclusion of subjects in the next dose level will be decided by the sponsor in consultation with a Data Monitoring Committee (DMC).
Receives: Drug: Radotinib HCl 50 mg

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Evaluation of safety parameters: Adverse Events

    Incidence and severity of treatment emergent AEs

    Measured: 12 months after dose administration

Secondary outcomes (13)

  1. Pharmacokinetics assessments of Radotinib HCl: Cmax

    The maximum (peak) observed drug concentration after dose administration

    Measured: 14 days after dose administration

  2. Pharmacokinetics assessments of Radotinib HCl: Tmax

    The time to reach maximum (peak) drug concentration after dose administration

    Measured: 14 days after dose administration

  3. Pharmacokinetics assessments of Radotinib HCl: Ctrough

    Trough plasma concentration (measured concentration at the end of a dosing interval at steady state)

    Measured: 14 days after dose administration

  4. Pharmacokinetics assessments of Radotinib HCl: AUCt

    Area under the plasma concentration-time curve from time zero to time t

    Measured: 14 days after dose administration

  5. Pharmacokinetics assessments of Radotinib HCl: AUCinf

    Area under plasma concentration-time curve from time 0 to infinity

    Measured: 14 days after dose administration

  6. Pharmacokinetics assessments of Radotinib HCl: AUC0-12h

    Area under the plasma concentration-time curve over the last 24-h dosing interval

    Measured: 14 days after dose administration

  7. Pharmacokinetics assessments of Radotinib HCl: t1/2

    Elimination half-life of Radotinib after dose administration

    Measured: 14 days after dose administration

  8. Pharmacokinetics assessments of Radotinib HCl: Vd/F

    Apparent volume of distribution after non-intravenous administration

    Measured: 14 days after dose administration

  9. Pharmacokinetics assessments of Radotinib HCl: CL/F

    Apparent total clearance of the drug from plasma after oral administration

    Measured: 14 days after dose administration

  10. Change from Baseline in the sum of MDS-UPDRS Parts I, II and III

    The Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a clinimetric assessment of subjective and objective symptoms and signs of Parkinson's disease created by the Movement Disorder Society.

    The MDS-UPDRS has four parts: Part I (non-motor experiences of daily living), Part II (motor experiences of daily living, Part III (motor examination) and Part IV (motor complications). Only Parts I, II and III will be completed in this study.

    MDS-UPDRS retains the four-scale structure with a reorganization of the various subscales. The subscale has a 0-4 rating, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Higher MDS-UPDRS scores reflect worse tremor/motor function. Larger differences will infer greater effect size for the intervention. Score drops over time imply improvement in tremor/motor function.

    Measured: 6 months

  11. Time from baseline to initiation of dopamine-replacement medication.

    Time from baseline to initiation of dopamine replacement therapy following randomization

    Measured: 6 months

  12. Change in health related quality of life as measured by a quality of life questionnaire (PDQ-39)

    The Parkinson's Disease Questionnaire (PDQ-39) is a 39-item quality of life questionnaire for patients with Parkinson's Disease (PD) that evaluates the 8 dimensions of mobility, activities of daily living, emotional well-being, stigma, social support, cognition, and communication. The PDQ-39 Single Index (SI) score is the weighted addition of scores on all 8 dimension and ranges from 0 (no disease impact) to 100 (severe disease impact).

    Measured: 12 months

  13. Subject's clinical global impression of change.

    The CGI Scale of Global Clinical Impressions (see Appendix VI) allows an overall assessment of the subject's condition. The CGI addresses the majority of mental disorders. In its first item, rated from 1 to 7 (the rating 1 corresponding to the normal state), it allows a good overall measurement of the subject's condition. The 2nd item proposes to the Investigator to evaluate the overall improvement of the subject compared to his/her condition at the admission to the research. As before, this item has 7 quantified degrees (from 1 = "very strongly improved" to 7 = "very strongly aggravated").

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Dec 2020
  2. Study start9 Sep 2021
  3. Primary completion2 Sep 2026
  4. Study completion30 Apr 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
43 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04691661
Sponsor's protocol ID
RT51EP1902
Status last verified
Sep 2026
First submitted
16 Dec 2020
Last updated
3 Sep 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Joshi D, Kulkarni M, Parekh P, Shah S, Greig NH, Acharya S. Targeting protein kinases in Parkinson's disease: the emerging role of phytoconstituents. Nutr Neurosci. 2025 Dec;28(12):1532-1563. doi: 10.1080/1028415X.2025.2531356. Epub 2025 Jul 18.

    PubMed 40680102

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Radotinib HCl 50 mg in people with Parkinson Disease, run by Il-Yang Pharm. Co., Ltd. at 7 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 36 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 3 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 7 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Evaluation of safety parameters: Adverse Events (time frame: 12 months after dose administration). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04691661, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in